KEY INCLUSION CRITERIA
Non-pregnant postmenarchal females with a diagnosis of VVC meeting the following criteria:
- Composite VSS minimum score of ≥4 with at least 2 signs or symptoms having a score of 2 (moderate) or greater
- Positive microscopic exam with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts
- Normal vaginal pH (≤4.5)
Single day of BREXAFEMME 600mg (two 150 mg tabs per dose, administered 12 hours apart).
Percentage of subjects with complete clinical response (VSS score of 0) at Day 10.
Sustained resolution of VVC signs and symptoms at Day 25.
Evaluated in a wide range of patient types.
Why evaluate efficacy using the VSS score?1
The VSS scale provides a comprehensive assessment of hallmark signs and symptoms of vaginal yeast infections, including:
Studied in patients with moderate-to-severe VSS5
of patients at baseline had a VSS score of ≥7